Oncology

Latest News

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

David Nguyen, MD | Image Credit: Tufts Medicine

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

By Maggie L. Shaw
David Nguyen, MD

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

By Mary Caffrey

July 23rd 2025

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

By AJMC Contributor

July 23rd 2025

Christine Pfaff, MBA, RPh | Image: LinkedIn

COA Welcomes Christine Pfaff, MBA, RPh, to Leadership Team

July 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

July 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 25th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Pathophysiology and Treatment Landscape of CLL

July 18th 2016

Pathophysiology and Treatment Landscape of CLL

July 18th 2016

UIC Study Supports Use of Adjuvant Chemotherapy in Stage II Colon Cancer

Surabhi Dangi-Garimella, PhD

According to the study published in Cancer, adjuvant chemotherapy in patients with early stage colon cancer results in clinically relevant improvement in overall survival.

July 18th 2016

Understanding and Mitigating the Financial Burden of Cancer Patients

Surabhi Dangi-Garimella, PhD

Drug prices have developed into the fastest growing segment of healthcare costs and are a significant burden on the patient's wallet, in addition to the cost of healthcare services. An Education Session at the annual meeting of the American Society of Clinical Oncology discussed potential solutions to ease this problem.

July 18th 2016

ASCO Study Finds Daratumumab Could Be Economical Over Pomalidomide—Dexamethasone in MM

Surabhi Dangi-Garimella, PhD

A poster presented at the annual meeting of the American Society of Clinical Oncology evaluated the cost per median month of survival for daratumumab and other novel treatments for multiple myeloma.

This Week in Managed Care: July 16, 2016

July 16th 2016

This Week in Managed Care: July 16, 2016

The top stories in managed care this week included coverage of JAMA’s special issue on healthcare transformation under the ACA, changes in the proposed 2017 Physician Fee Schedule promoting value-based care, and more.

July 15th 2016

Disparity in Bone Density Assessment in Older Women Treated With AI for Breast Cancer

Surabhi Dangi-Garimella, PhD

Despite their known risk, only half the women over 85 years of age in a cohort being evaluated had their baseline bone density tested prior to initiating treatment.

July 15th 2016

Aggressive Cancer Care Widely Used Among Patients at the End of Life

Many patients, 65 years or younger, are still receiving aggressive cancer treatment in their final months of life despite Choosing Wisely recommendations encouraging symptom-directed palliative care.

July 15th 2016

Lessons to Learn From the NICE Cancer Care Model

Surabhi Dangi-Garimella, PhD

On the first day of the annual meeting of the American Society of Clinical Oncology, healthcare experts from the United States, Canada, and the United Kingdom, compared and contrasted the care models that are widely adopted in each nation.

Dr Debra Patt Breaks Down Rising Cancer Care Costs

July 15th 2016

Dr Debra Patt Breaks Down Rising Cancer Care Costs

Although cancer care costs are rising, it is proportional to the total utilization of healthcare resources and spending growth is happening more in areas that have seen innovation, explained Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology.

July 14th 2016

NEJM Study First to Identify Mutations Responsible for Relapse in PD-1 Inhibitor—Treated Melanoma

Surabhi Dangi-Garimella, PhD

Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin gene were found responsible for lack of response to interferon gamma.

July 14th 2016

Zeroing in on Predictive Biomarkers for Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

During a clinical session at the annual meeting of the American Society of Clinical Oncology, researchers were tasked with sharing their data on any breakthroughs or leads with biomarkers for the new immunotherapies.

July 14th 2016

CAR-T Cells in Leukemia and Lymphoma

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Clinical Oncology, results were presented from a phase 1/2 trial in which patients with relapsed or refractory CD19+ B-cell malignancies were treated with CD19 CAR-T cells.

July 13th 2016

EndoPredict Better Than Oncotype DX in Predicting DR in Breast Cancer

Surabhi Dangi-Garimella, PhD

A study has found that an 8-gene signature score, combined with nodal status and tumor size, obtained from the EndoPredict breast cancer test might be more accurate at predicting the recurrence of breast cancer, compared with the recurrence score of Oncotype DX.

July 13th 2016

FDA Releases Hold on Juno's ROCKET Trial

Surabhi Dangi-Garimella, PhD

The ROCKET trial was halted last week following news of 3 patient deaths due to cerebral edema.

July 13th 2016

Promising Results With Combination Immunotherapy in Solid Tumors and Leukemia

Surabhi Dangi-Garimella, PhD

As immunotherapy-particularly the checkpoint inhibitors-continues to show promise in solid as well as liquid tumors, clinicians have been evaluating these agents in combination to improve efficacy and outcomes.

July 13th 2016

Nivolumab Safe in Glioblastoma

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Clinical Oncology, held June 3-7, 2016, phase 1 data from the CheckMate 143 trial was presented during a poster session.

July 12th 2016

Safety, Efficacy of Balugrastim to Treat Chemotherapy-Induced Neutropenia

Researchers assessed balugrastim’s efficacy, safety, and tolerability in 4 different clinical trials and found it to be a suitable alternative to pegfilgrastim in regard to reducing the mean duration of severe neutropenia.

July 12th 2016

Advertising by Cancer Centers Tripled Over the Last Decade

Surabhi Dangi-Garimella, PhD

Promotional advertising by cancer centers has seen a dramatic spike in recent years, with 890 cancer centers spending $173 million for advertising in 2014.

July 11th 2016

NCI Predicts a "Silver Tsunami" of Cancer Survivors by 2040, 75% Will Be Over 65

Surabhi Dangi-Garimella, PhD

The National Cancer Institute (NCI) estimates that the aging US population will contribute to a substantial increase in the number of older cancer survivors over the next 25 years.

July 11th 2016

Treating High Cholesterol Could Improve Cancer Outcomes

Surabhi Dangi-Garimella, PhD

According to a study conducted in the United Kingdom, statins can reduce the risk of dying from breast, prostate, lung, and bowel cancer.

This Week in Managed Care: July 9, 2016

July 9th 2016

This Week in Managed Care: July 9, 2016

This week in managed care, the top stories included a report on how much Americans spend on complementary health approaches, more trouble with the Affordable Care Act's risk adjustment program, and researchers linked the BRCA1 gene to deadly uterine cancer.

July 9th 2016

Predicting Risk of Severe Neutropenia With a Nomogram

A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.

July 8th 2016

5 Health IT Highlights From the NCCN Policy Summit

Experts at a summit convened by the National Comprehensive Cancer Network (NCCN) agreed that progress in health information technology can help break the walls between compartmentalized data that lives within distinct data systems, to improve patient outcomes.

July 8th 2016

Increased Prevalence, New Biologics Driving Urologic Cancer Market

The rising prevalence of urologic cancers, along with the increased use of hormone therapies and the approval of novel biologics, is driving strong growth in the urologic cancer market globally through 2022.

July 7th 2016

Juno's ROCKET Trial Stopped Following Deaths Due to Cerebral Edema

Surabhi Dangi-Garimella, PhD

The FDA has asked Juno Therapeutics to halt the phase 2 clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, the ROCKET trial.

July 7th 2016

Dissolving Data Silos and Improving Access to Health IT Essential in Oncology Care

Surabhi Dangi-Garimella, PhD

Panelists at the policy summit hosted by National Comprehensive Cancer Network agreed that sharing information can help create a learning system that can improve patient outcomes.

Dr Michael Kolodziej Explains the Benefits of Aetna's Oncology Medical Home Program

July 7th 2016

Dr Michael Kolodziej Explains the Benefits of Aetna's Oncology Medical Home Program

Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, said that the evaluation of academic medical centers has allowed the company to examine what lies at the heart of creating optimal patient outcomes and experiences.

July 6th 2016

ASCO Publishes Novel Guideline-Development Approach

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology (ASCO) has published a paper that shares the various innovative approaches developed by the society for guideline development and implementation.

Making Informed Treatment and Coverage Decisions in Multiple Myeloma

July 6th 2016

Making Informed Treatment and Coverage Decisions in Multiple Myeloma

Diagnostic Testing and Stem Cell Transplants in Multiple Myeloma: The Health Plan Approach

July 6th 2016

Diagnostic Testing and Stem Cell Transplants in Multiple Myeloma: The Health Plan Approach

...

98 99 100 101 102 103 104 105 106

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions